160 related articles for article (PubMed ID: 25638793)
1. Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment.
Helmreich I; Wagner S; König J; Kohnen R; Szegedi A; Hiemke C; Tadić A
J Affect Disord; 2015 Apr; 175():199-208. PubMed ID: 25638793
[TBL] [Abstract][Full Text] [Related]
2. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
[TBL] [Abstract][Full Text] [Related]
5. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
6. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression.
Tadić A; Helmreich I; Mergl R; Hautzinger M; Kohnen R; Henkel V; Hegerl U
J Affect Disord; 2010 Jan; 120(1-3):86-93. PubMed ID: 19428118
[TBL] [Abstract][Full Text] [Related]
7. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
Szegedi A; Müller MJ; Anghelescu I; Klawe C; Kohnen R; Benkert O
J Clin Psychiatry; 2003 Apr; 64(4):413-20. PubMed ID: 12716243
[TBL] [Abstract][Full Text] [Related]
8. Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters.
Guo T; Xiang YT; Xiao L; Hu CQ; Chiu HF; Ungvari GS; Correll CU; Lai KY; Feng L; Geng Y; Feng Y; Wang G
Am J Psychiatry; 2015 Oct; 172(10):1004-13. PubMed ID: 26315978
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to changes during antidepressant treatment: a comparison of unidimensional subscales of the Inventory of Depressive Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients with mild major, minor or subsyndromal depression.
Helmreich I; Wagner S; Mergl R; Allgaier AK; Hautzinger M; Henkel V; Hegerl U; Tadić A
Eur Arch Psychiatry Clin Neurosci; 2012 Jun; 262(4):291-304. PubMed ID: 21959915
[TBL] [Abstract][Full Text] [Related]
10. Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated With Mirtazapine.
Funaki K; Nakajima S; Suzuki T; Mimura M; Uchida H
J Clin Pharmacol; 2016 Sep; 56(9):1111-9. PubMed ID: 26813241
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD).
Ballesteros J; Bobes J; Bulbena A; Luque A; Dal-Ré R; Ibarra N; Güemes I
J Affect Disord; 2007 Sep; 102(1-3):93-9. PubMed ID: 17258323
[TBL] [Abstract][Full Text] [Related]
12. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.
Szegedi A; Jansen WT; van Willigenburg AP; van der Meulen E; Stassen HH; Thase ME
J Clin Psychiatry; 2009 Mar; 70(3):344-53. PubMed ID: 19254516
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care.
Romeo R; Patel A; Knapp M; Thomas C
Int Clin Psychopharmacol; 2004 May; 19(3):125-34. PubMed ID: 15107654
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression.
Bech P
Int J Neuropsychopharmacol; 2001 Dec; 4(4):337-45. PubMed ID: 11806859
[TBL] [Abstract][Full Text] [Related]
15. Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy.
Lin CH; Park C; McIntyre RS
J Affect Disord; 2019 Jun; 253():154-161. PubMed ID: 31035216
[TBL] [Abstract][Full Text] [Related]
16. Predictors of remission with placebo using an integrated study database from patients with major depressive disorder.
Nelson JC; Zhang Q; Deberdt W; Marangell LB; Karamustafalioglu O; Lipkovich IA
Curr Med Res Opin; 2012 Mar; 28(3):325-34. PubMed ID: 22292447
[TBL] [Abstract][Full Text] [Related]
17. Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials.
Boessen R; Groenwold RH; Knol MJ; Grobbee DE; Roes KC
J Affect Disord; 2013 Mar; 145(3):363-9. PubMed ID: 22959683
[TBL] [Abstract][Full Text] [Related]
18. Early improvement in HAMD-17 and HAMD-6 scores predicts ultimate response and remission for depressed patients treated with fluoxetine or ECT.
Lin HS; Lin CH
J Affect Disord; 2019 Feb; 245():91-97. PubMed ID: 30368075
[TBL] [Abstract][Full Text] [Related]
19. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials.
Gomeni R; Merlo-Pich E
Br J Clin Pharmacol; 2007 May; 63(5):595-613. PubMed ID: 17488364
[TBL] [Abstract][Full Text] [Related]
20. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
